– September 1, 2006
September 1, 2006
View Issues
-
Rare and Complex (≥ 5) Chromosomal Abnormalities Predict A Worse Outcome in Older AML Patients
Outcomes for older adults with AML are generally poor. Cytogenetics and outcomes of 635 adults 60 years and older from CALGB cooperative group treatment trials were evaluated. -
Fludarabine and the Older Patient
In a retrospective analysis from MacCallum Cancer Center in Melbourne, Australia, fludarabine-associated toxicities were examined in the context of patient age for those being treated for indolent lymphoma or chronic lymphocytic leukemia. -
CA125 Kinetics: Prognostic Value for Patients with Advanced Ovarian Cancer
A multicenter study of serial CA125 levels during chemotherapy for advanced ovarian cancer demonstrates that half-life and nadir concentration are strong and independent predictors of disease-free and overall survival. -
Hemoglobin Drop and Prognosis in Patients with Advanced Prostate Cancer
Anemia prior to therapy has been established as a negative prognostic factor for patients with metastatic prostate cancer. -
New Light on the Link Between Chronic Stress and Ovarian Cancer Tumorigenesis
Blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer. -
Pharmacology Watch
What is the role of raloxifene for the treatment of osteoporosis and breast cancer prevention? Raloxifene is a selective estrogen-receptor modulator similar to tamoxifen. -
Clinical Briefs in Primary Care Supplement